Inretail Peru Corp. · BVL:INRETC1
Inretail Peru — Q4 2019 Earnings Presentation
37 slides from Inretail Peru's earnings presentation, March 2020
Slide 1: Corporate Presentation
The leading Peruvian retailer CORPORATE PRESENTATION March 2020
Slide 2: Agenda
1 INRETAIL OVERVIEW 2 INVESTMENT THESIS 3 Q4’19 FINANCIAL RESULTS 4 CAPEX GUIDANCE 2020-2022 5 APPENDIX
Slide 3: InRetail Overview
InRetail Overview Peruvian multi-format retailer, with presence in the Andean region through the Pharma business Leading positions in Peru in its 3 segments #1 food retail chain #1 pharmacy chain and distributor in Peru, with presence in the Andean region #1 shopping center operator Cont
Slide 4: InRetail is part of one of Peru's leading business groups
InRetail is part of one of Peru’s leading business groups Education Float 28.8% 1/ BVL: INRETC1 2019 Intercorp metrics: a More than USD 6.6 billion in sales in 2019 2 listed companies with a combined market capitalization of ~ USD 6.3 billion as of December, 2019 More than 82,000 employees 1/
Slide 5: 2019 Financial and Operational Snapshot
2019 Financial and Operational Snapshot Million Soles (S/ mm) Food Shopping Pharma Retail Malls 1/ 2019 figures (S/ mm; %) + + = Revenues 5,762 6,852 543 13,070 % Revenues Contribution 44% 52% 4% Adj. EBITDA (Pre-IFRS 16) 2/ 400 711 325 1,427 % EBITDA Contribution 28% 49% 23% Adj. EBITDA Margin 6.9%
Slide 6: Agenda
1 INRETAIL OVERVIEW 2 INVESTMENT THESIS 3 Q4’19 FINANCIAL RESULTS 4 CAPEX GUIDANCE 2020-2022 5 APPENDIX
Slide 7: Investment Thesis
Investment Thesis The leading multi-format retailer in a growing and underpenetrated Peruvian market 1 Proven track record Consistent organic growth and successful integration of acquisitions for delivering Seasoned management team with broad industry experience sustainable and profitable growth
Slide 8: Proven track record of profitable growth
Proven track record of profitable growth Revenues (S/ million) 13,070 SPSA TURNAROUND PERIOD 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Acquisition of SPSA Plaza Vea Agreement Acquisition InRetail’s Strategic Opening of Mass format Plaza Vea Quicorp Opening of SPSA fr
Slide 9: Investment Thesis
Investment Thesis The leading multi-format retailer in a growing and underpenetrated Peruvian market 1 Proven track record Consistent organic growth and successful integration of acquisitions for delivering Seasoned management team with broad industry experience sustainable and profitable growth
Slide 10: Fastest growing economy boosts emerging middle class
Fastest growing economy boosts emerging middle class Real GDP Growth Population by Socio-Economic Category CAGR 2012 - 2018 CAGR 2018 - 2021 1.8% 1.1% Annual SEC 2007 2018 Income 3.7% 3.9% 2.8% % of total population 1.9% A $ 46,992 Perú Latin America 1/ Perú Latin America 1/ 8% 12% Source: IMF – Wor
Slide 11: Significant upside potential for modern retail
Significant upside potential for modern retail Food Retail Pharmacies Shopping Malls Penetration as a % of Total Sales - 2018 Healthcare Expenditure as % of GDP - 2018 Malls per million people - 2018 Sales area per capita: Peru 0.25 sqm vs Mexico 0.40 sqm 70% 8.0 Mean ex-Peru: 62% 9.7% 54.4% 59% 9.2
Slide 12: Retail market in Peru in early stage of development
Retail market in Peru in early stage of development Global Retail Development Index Opportunities Peru top-ranked LatAm country in the GRDI Opening Peaking Maturing Closing 2019 Ranking Mexico (2009) 1. China 13. Peru Brazil (2013) 5. Indonesia 16. Brazil Peru (2015) 10. Colombia 21. Paraguay Brazil
Slide 13: Investment Thesis
Investment Thesis The leading multi-format retailer in a growing and underpenetrated Peruvian market 1 Proven track record Consistent organic growth and successful integration of acquisitions for delivering Seasoned management team with broad industry experience sustainable and profitable growth
Slide 14: Largest nationwide footprint of premier retail locations
Largest nationwide footprint of premier retail locations Food Retail Pharmacies Shopping Malls 108 Spmkts 5 Economax 2,077 Stores 2/ 21 Malls 405 Mass 19 Mimarket (16) (58) (97) (11) (6) Piura (2) (2) (83) (64) Chiclayo (1) Cajamarca (2) (1) (44) (131) Trujillo (5) (63) (34) Chimbote (3) (1) (13) (2
Slide 15: Quarterly Openings and SSS By Segment
Quarterly Openings and SSS By Segment Openings Same Store Sales (SSS) Food Retail Food Retail 2018: 7.9% Sales Area (‘000 sqm) 2019: 4.1% 372 375 380 395 9.5% 361 47 53 56 61 66 7.8% 23 23 23 23 Mass 4.1% Economax 296 296 296 296 306 2.0% 1.5% Spmkts Q4’18 Q1’19 Q2’19 Q3’19 Q4’19 Q4’18 Q1’19 Q2’19 Q
Slide 16: Food Retail Segment
Food Retail Segment Formats Sales area # of % of Format range (sqm) Stores Revenues 1/ Every-Day-Low-Price strategy for Plaza Vea stores Compact Hypermarket 2,000 – 5,000 70 73% 2/ New discount formats Mass and Mimarket to capture untapped demand and accelerate penetration of traditional trade S
Slide 17: Pharma Segment: Pharmacies
Pharma Segment: Pharmacies Leading pharmacy player in Peru with +2,000 stores Strong cash flow generation in a Capex light business model Solid track record in a resilient consumer non-discretionary industry Every-Day-Low-Prices Discounts and promotions Focused on offering the Targeted dis
Slide 18: Pharma Segment: Manufacturing, Distribution and Marketing
Pharma Segment: Manufacturing, Distribution and Marketing Best-in-class distribution network Vertical integration with Pharmacy chains (% of sales) Leading pharmaceutical Pharmacy chains distributor in Peru with presence in the Andean region 46.0% Other channels Vital link between manufacturers 54%
Slide 19: Shopping Malls Segment
Shopping Malls Segment Shopping Malls Sales Sales (S/ millions) 2018 Nationwide premium portfolio of 21 locations, with 807k sqm of GLA 6,232 4,756 Preferred partner for local and international tenants: 3,505 High tenant renewal rates and low concentration of renewal per 2,761 2,686 2,597 year
Slide 20: Agenda
1 INRETAIL OVERVIEW 2 INVESTMENT THESIS 3 Q4’19 FINANCIAL RESULTS 4 CAPEX GUIDANCE 2020-2022 5 APPENDIX
Slide 21: Q4'19 Consolidated Financial Results
Q4’19 Consolidated Financial Results Million Soles (S/ mm) Highlights Revenues Low single-digit growth in Revenues, mainly explained by a +6.8% contraction in the MDM unit of our Pharma segment 13,070 12,243 Solid growth in Adjusted EBITDA in our three segments +2.9% Consolidated Gross Margin,
Slide 22: Food Retail
Food Retail S/ mm Q4'19 Q4'18 Var % 2019 Var % Revenues 1,573 1,459 7.8% 5,762 12.0% Gross Profit 424 403 5.2% 1,516 11.4% Adj. EBITDA 1/ (Pre-IFRS 16) 134 117 14.7% 400 16.3% Gross Mg 26.9% 27.6% -68 bps 26.3% -14 bps Adj. EBITDA Mg 1/ (Pre-IFRS 16) 8.5% 8.0% 52 bps 6.9% 25 bps Net opening of 34k s
Slide 23: Pharma
Pharma Pharmacies 1/ MDM 1/ Total S/ mm Q4'19 Var % Q4'19 Var % Q4'19 Var % 2019 Var % Revenues 1,275 1.9% 633 -11.7% 1,740 -1.7% 6,852 2.2% Gross Profit (Pre-IFRS 16) 481 5.1% 87 22.7% 561 11.5% 2,130 10.1% Adj. EBITDA 2/ (Pre-IFRS 16) 176 23.1% 31 30.1% 206 23.0% 711 31.7% Gross Mg 37.7% 36.6% 13.
Slide 24: Shopping Malls
Shopping Malls S/ mm Q4'19 Q4'18 Var % 2019 Var % Revenues 154 138 11.2% 543 6.9% Gross Profit (Pre-IFRS 16) 104 93 11.3% 362 5.8% Adj. EBITDA 1/ (Pre-IFRS 16) 93 85 9.1% 325 4.7% Gross Mg 67.4% 67.4% 4 bps 66.8% -70 bps Net Rental Mg 2/ (Pre-IFRS 16) 79.6% 80.0% -41 bps 78.5% -118 bps Revenue growt
Slide 25: Consolidated Net Income
Consolidated Net Income Million Soles (S/ mm) Net Income (Pre-IFRS 16) 1/ Net Income Breakdown (Pre-IFRS 16) 1/ 624 5 21 -82 99.8% 124 260 -0 225 62 260 130 130 Q4’18 Q4’19 2018 2019 Net EBITDA Flat Net Higher Net FX Lower Higher Net Income Growth Financial Mark to Effect D&A Tax Income Q4’18 Expens
Slide 26: Capex and Cash-Flow Breakdown
Capex and Cash-Flow Breakdown Million Soles (S/ mm) Consolidated CAPEX Cash-Flow Breakdown 2018: S/998 mm 2019: S/847 mm 1/ 335 -847 263 243 249 1,533 180 -35 223 196 -400 183 152 -132 740 -22 643 155 Q1’18 Q2’18 Q3’18 Q4’18 Q1’19 Q2’19 Q3’19 Q4’19 Starting Operating CAPEX Financial Financial Divide
Slide 27: Consolidated Financial Debt
Consolidated Financial Debt Million Soles (S/ mm) Consolidated Financial Debt 1/ USD Exposure Net Debt/Adj. EBITDA Debt/Adj. EBITDA 4.8x 4.0x 4.0x 4.0x 3.9x 3.8x 3.6x 3.6x 39% 42% 40% 4.3x 47% 3.3x 3.3x 49% 3.6x 3.5x 3.5x 3.4x 3.4x 3.2x 3.1x 2.8x 23% 3% 2% 2.5x 23% 22% 48% 51% 38% 35% 38% 2014 2015
Slide 28: Debt By Segment
Debt By Segment 1/ Million Soles (S/ mm) Total Consolidated Debt: S/5,250 mm Debt / Adj. EBITDA: 3.6x Net Debt / Adj. EBITDA: 3.1x 3.4x 3.4x 3.4x 3.7x 5.6x 5.7x 5.7x 5.8x 5.8x 3.5x 3.0x 3.1x 3.2x 3.1x 2.7x 3.1x 2.9x 3.1x 3.0x 5.1x 5.1x 5.2x 2.8x 4.0x 5.1x 4.9x 2.6x 2.8x 2.6x 2.6x 2.2x 2.4x 2.0x 3.1x
Slide 29: IFRS 16 EBITDA Bridge
IFRS 16 EBITDA Bridge Million Soles (S/ mm) 1/ Q4’19 Accounting Operating Profit Q4’19 501.5 102.7 182.9 249.6 Excluded rental expenses of assets -92.6 -34.3 -67.9 -2.4 with right-of-use as per IFRS 16 D&A of PP&E 2/ -64.4 +41.1 +25.2 -156.4 Additional depreciation of assets with +85.0 +24.9 +65.9 +
Slide 30: IFRS 16 Net Income Reconciliation
IFRS 16 Net Income Reconciliation Million Soles (S/ mm) 1/ Q4’19 Accounting Net Income Q4’19 271.0 Rental expenses of assets with right-of-use as per IFRS 16 -92.6 Financial expenses from debt of assets with right-of-use as per IFRS 16 +26.0 Exchange rate income from debt of assets with right-of-use
Slide 31: Agenda
1 INRETAIL OVERVIEW 2 INVESTMENT THESIS 3 Q4’19 FINANCIAL RESULTS 4 CAPEX GUIDANCE 2020-2022 5 APPENDIX
Slide 32: CAPEX Guidance 2020-2022
CAPEX Guidance 2020-2022 Projected CAPEX of S/2.1 B for 2020-2022 Food Retail By Segment Plaza Vea: 2 new Plaza Vea stores in 2020 (+6.9k sqm of sales area) Shopping 2 to 3 new Plaza Vea stores per year in 2021 and 2022 (avg. of 3.5k Malls 33% sqm of sales area per store) Economax: 55% Food Reta
Slide 33: Appendix
1 INRETAIL OVERVIEW 2 INVESTMENT THESIS 3 Q4’19 FINANCIAL RESULTS 4 CAPEX GUIDANCE 2020-2022 5 APPENDIX
Slide 34: Composition of Stores by Age
Composition of Stores by Age Food Retail 5% 8% 9% 8% 8% 8% 10% 11% 6% 14% 16% 14% 12% 6% 5% 4% 4% 7% 9% 4% 6% 5% 8% 6% 5% 7% 7% 8% 12% 5% 7% 3% 4% 6% 7% 6% 81% 81% 82% 82% 82% 79% 77% 76% 74% 73% 73% 71% Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Mature 2-3 years 1-2 yea
Slide 35: Cash Cycle
Cash Cycle Food Retail Pharma 1/ 141 121 120 119 121 117 110 108 114 105 104 106 84 89 90 83 77 75 76 79 78 72 66 70 35 28 27 25 25 25 23 25 3 3 3 4 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 -16 -10 -13 -13 -4 -14 -23 -24 -22 -19 -29 -32 Days Acc Payables Inventory Turn
Slide 36: Disclaimer
This material was prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities. This presentation may include forward-looking statements or statements about events or circumstances which have not yet occurred. We have based these f
Slide 37: For more information contact
For more information contact: ir@inretail.pe www.inretail.pe